about
Serological identification and bioinformatics analysis of immunogenic antigens in multiple myelomaAzelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia.Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinomaChimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of RasEfficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia.Human Endogenous Retroviruses-K (HML-2) Expression Is Correlated with Prognosis and Progress of Hepatocellular Carcinoma.Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cellsPrognostic Value of Elevated Red Blood Cell Distribution Width in Chinese Patients with Multiple Myeloma.A novel curcuminoid exhibits enhanced antitumor activity in nasopharyngeal carcinoma.Current treatment options of T cell-associated immunotherapy in multiple myeloma.Leptin-LepRb Expressed in Gastric Cancer Patients and Related to Cancer-Related DepressionA novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma.A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia.MMSA-1 expression pattern in multiple myeloma and its clinical significance.Reactive Oxygen Species-Mediated Tumor Microenvironment Transformation: The Mechanism of Radioresistant Gastric Cancer.Efficacy of SXN in the Treatment of Iron Deficiency Anemia: A Phase IV Clinical TrialReactive Oxygen Species Are Involved in the Development of Gastric Cancer and Gastric Cancer-Related Depression through ABL1-Mediated Inflammation Signaling Pathway
P50
Q28274681-8C3C0154-E35B-4644-89B5-1301B7429142Q33785633-BB250BAB-0532-4EAD-BCFD-66546A66B785Q34575479-EDE850EF-C6B4-4AF9-9AE7-2F6245019587Q36110284-8657A8E4-5ECE-45D7-8D40-C6B546F17E83Q37310474-4A2004D1-78BE-4250-AE34-EE20D0C8D00EQ37539094-E94392D7-E342-4950-8298-808767C84F6FQ37643955-B7476458-839B-4AAE-9FA5-4F434BC45183Q37708924-3B4B378F-E8EE-4D5B-927D-F28503037F5BQ38699353-5E6744C7-B532-4065-B510-D65B47537661Q38785893-6158156F-6E08-4FB2-8417-571C45241B02Q39102170-0520A111-4438-4282-8A47-42F69E412B2DQ42097342-2535539C-B625-40EC-ACCF-42ED00A1274EQ47829053-5B7E4939-FF7F-4084-8642-8BAA66E62AF3Q48144595-0828FB8A-2CA1-4891-9203-86FE44795079Q48267537-3278BFA7-AE09-4415-B407-B9E03C042806Q52907776-AFEAB516-4557-44F2-8AB6-AA3303A069E1Q54939968-EBBD1BF0-ED73-4986-BBB7-B3C291F7D54AQ64070847-4A5374A5-6790-4286-BC02-7E73B580075FQ92511862-BDC0FEE7-C6F9-4497-A462-31A7BD9F4C96
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-0982-0382
@en
name
Fuling Zhou
@ast
Fuling Zhou
@en
Fuling Zhou
@es
Fuling Zhou
@nl
type
label
Fuling Zhou
@ast
Fuling Zhou
@en
Fuling Zhou
@es
Fuling Zhou
@nl
prefLabel
Fuling Zhou
@ast
Fuling Zhou
@en
Fuling Zhou
@es
Fuling Zhou
@nl
P106
P31
P496
0000-0003-0982-0382